As of December 2020, no oral nicotine product sold in the USA has been approved as a cessation medication and none have been granted FDA authorisation to be marketed as modified-risk tobacco products .9 The FDA has the authority to restrict the use of false or misleading claims in oral nicotine advertising that may suggest to consumers that there is reduced harm or risk in using the product.10 This is particularly important given evidence that exposure to implicit or explicit reduced-harm claims in tobacco advertising is associated with forming more positive, pro-tobacco attitudes, and thus, can lead to greater product use.1115 While numerous studies document the claims used to promote smokeless tobacco products, like snus or moist-snuff pouches (eg, smoke-free, spit-free, use anywhere)1618 and other non-combustible products like e-cigarettes (eg, goodbye cigarette, hello vapour),1921 data on the type of claims used to promote oral nicotine products is limited
Das Hauptproblem liegt woanders: Nur im Vaping-Geschft gelingt es BAT, den Marktanteil aus dem Zigarettenverkauf zu halten oder gar zu bertreffen
4 shows the annual mean PM 2.5 concentrations in Canada and the USA that are related to the fires in each country
The Hosts may also take positions inconsistent with the views expressed in its messages on the Podcast.
